Liquidia Co. (NASDAQ:LQDA) General Counsel Sells $28,619.36 in Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 2,576 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $28,619.36. Following the sale, the general counsel now owns 486,048 shares in the company, valued at approximately $5,399,993.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Russell Schundler also recently made the following trade(s):

• On Tuesday, September 3rd, Russell Schundler sold 710 shares of Liquidia stock. The stock was sold at an average price of $9.50, for a total value of $6,745.00.

Liquidia Trading Down 1.5 %

Shares of LQDA opened at $11.46 on Friday. The company’s 50 day simple moving average is $10.42 and its 200-day simple moving average is $11.97. Liquidia Co. has a 12-month low of $5.71 and a 12-month high of $16.99. The firm has a market cap of $875.70 million, a PE ratio of -7.35 and a beta of 0.22.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. The business had revenue of $3.66 million for the quarter, compared to analysts’ expectations of $7.92 million. As a group, equities research analysts forecast that Liquidia Co. will post -1.69 EPS for the current fiscal year.

Hedge Funds Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently made changes to their positions in LQDA. Patient Square Capital LP purchased a new stake in Liquidia during the 1st quarter valued at approximately $105,942,000. Farallon Capital Management LLC acquired a new position in shares of Liquidia in the first quarter valued at approximately $30,311,000. Sapient Capital LLC purchased a new stake in shares of Liquidia during the third quarter worth approximately $1,336,000. BNP Paribas Financial Markets lifted its holdings in shares of Liquidia by 119.4% during the first quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock worth $3,396,000 after purchasing an additional 125,315 shares during the period. Finally, HighVista Strategies LLC acquired a new stake in shares of Liquidia during the second quarter worth $1,461,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on LQDA. BTIG Research decreased their price target on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, August 19th. Lifesci Capital assumed coverage on Liquidia in a research report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price on the stock. Scotiabank started coverage on Liquidia in a report on Wednesday. They issued a “sector outperform” rating and a $30.00 price target for the company. Oppenheimer started coverage on shares of Liquidia in a report on Tuesday, June 25th. They set a “market perform” rating on the stock. Finally, Raymond James upgraded shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Liquidia currently has a consensus rating of “Moderate Buy” and an average price target of $24.67.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).